ACIP voted in favor of updates to the pneumococcal vaccination recommendations that (1) adults 65 years of age and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown, and (2) adults 19 to 64 years of age with certain underlying health conditions (including diabetes; chronic heart, lung, and liver disease; HIV) or other disease risk factors (smoking, alcoholism) who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine.
Vaccination with a pneumococcal conjugate vaccine is recommended, either 20-valent (PCV20; Prevnar 20) or 15-valent (PCV15; Vaxneuvance). If PCV15 is used, it should be followed by a dose of Pneumovax 23 (PPS23).
The CDC’s final recommendations will be published in the Morbidity and Mortality Weekly Report.
